Group 2 innate lymphoid cells boost CD8⁺ T-cell activation in anti-tumor immune responses.

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-01-01 DOI:10.1080/2162402X.2023.2243112

Jing Wen, Shipeng Cheng, Ran Wang, Yuying Huang, Long Xu, Liyan Ma, Zhiyang Ling, Jinfu Xu, Deping Zhao, Yaguang Zhang, Bing Sun

{"title":"Group 2 innate lymphoid cells boost CD8+ T-cell activation in anti-tumor immune responses.","authors":"Jing Wen, Shipeng Cheng, Ran Wang, Yuying Huang, Long Xu, Liyan Ma, Zhiyang Ling, Jinfu Xu, Deping Zhao, Yaguang Zhang, Bing Sun","doi":"10.1080/2162402X.2023.2243112","DOIUrl":null,"url":null,"abstract":"Group 2 innate lymphoid cells (ILC2s) are essential for orchestrating type 2 immune responses during allergic airway inflammation and infection. ILC2s have been reported to play a regulatory role in tumors; however, this conclusion is controversial. In this study, we showed that IL-33-activated ILC2s could boost CD8+ T-cell function through direct antigen cross-presentation. After activation by IL-33, ILC2s showed an enhanced potential to process antigens and prime CD8+ T cell activation. Activated ILC2s could phagocytose exogenous antigens in vivo and in vitro, promoting antigen-specific CD8+ T cell function to enhance antitumor immune responses. Administration of OVA-loaded ILC2s induces robust antitumor effects on the OVA-expressing tumor model. These findings suggested that the administration of tumor antigen-loaded ILC2s might serve as a potential strategy for cancer treatment.","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":"12 1","pages":"2243112"},"PeriodicalIF":7.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/dd/KONI_12_2243112.PMC10413917.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2023.2243112","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Group 2 innate lymphoid cells (ILC2s) are essential for orchestrating type 2 immune responses during allergic airway inflammation and infection. ILC2s have been reported to play a regulatory role in tumors; however, this conclusion is controversial. In this study, we showed that IL-33-activated ILC2s could boost CD8⁺ T-cell function through direct antigen cross-presentation. After activation by IL-33, ILC2s showed an enhanced potential to process antigens and prime CD8⁺ T cell activation. Activated ILC2s could phagocytose exogenous antigens in vivo and in vitro, promoting antigen-specific CD8⁺ T cell function to enhance antitumor immune responses. Administration of OVA-loaded ILC2s induces robust antitumor effects on the OVA-expressing tumor model. These findings suggested that the administration of tumor antigen-loaded ILC2s might serve as a potential strategy for cancer treatment.

Abstract Image

查看原文本刊更多论文

2组先天淋巴样细胞促进CD8+ t细胞激活抗肿瘤免疫应答。

2组先天淋巴样细胞(ILC2s)在过敏性气道炎症和感染期间协调2型免疫反应是必不可少的。据报道，ILC2s在肿瘤中发挥调节作用;然而，这个结论是有争议的。在本研究中，我们发现il -33激活的ILC2s可以通过直接抗原交叉递呈增强CD8+ t细胞的功能。被IL-33激活后，ILC2s显示出处理抗原和启动CD8+ T细胞活化的增强潜力。激活的ILC2s能够在体内外吞噬外源抗原，促进抗原特异性CD8+ T细胞功能，增强抗肿瘤免疫应答。加载ova的ILC2s对表达ova的肿瘤模型具有较强的抗肿瘤作用。这些发现表明，给药肿瘤抗原负载ILC2s可能是一种潜在的癌症治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.